PROLIA Drug Profile

Summary for Tradename: PROLIA

High Confidence Patents:	49
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for PROLIA
Recent Clinical Trials:	See clinical trials for PROLIA

See drug prices for PROLIA

Recent Clinical Trials for PROLIA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Xentria, Inc.	PHASE3
Qilu Pharmaceutical Co., Ltd.	PHASE3
Mabwell (Shanghai) Bioscience Co., Ltd.	PHASE3

See all PROLIA clinical trials

Pharmacology for PROLIA

Mechanism of Action	RANK Ligand Blocking Activity
Established Pharmacologic Class	RANK Ligand Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PROLIA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PROLIA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	PROLIA	denosumab	Injection	125320		2035-12-01	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320		2038-07-18	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320		2034-12-09	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320		2035-05-13	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320		2039-01-29	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320		2040-02-05	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320		2039-08-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for PROLIA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	PROLIA	denosumab	Injection	125320		2033-06-06	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320		2036-12-20	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320		2031-10-05	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320		2037-05-22	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320		2035-07-16	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320		2037-06-21	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320		2032-04-20	Patent claims search

International Patents for PROLIA

Country	Patent Number	Estimated Expiration
European Patent Office	2601287
Malaysia	202479
Canada	2938079
Canada	2947887
South Korea	102370714
Japan	2017519497
Ukraine	78966

Supplementary Protection Certificates for PROLIA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
132010901893988	Italy		PRODUCT NAME: DENOSUMAB(PROLIA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/10/618/001-004, 20100526
CA 2010 00031	Denmark
2010C/038	Belgium		PRODUCT NAME: DENOSUMAB; AUTHORISATION NUMBER AND DATE: EU/1/10/618/001 20100528
44/2010	Austria		PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100526
300467	Netherlands		PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100528
1090037-1.L	Sweden		PRODUCT NAME: DENOSUMAB; REG. NO/DATE: EU/1/10/618/001 20100526
C00911342/01	Switzerland		PRODUCT NAME: DENOSUMABUM; REGISTRATION NO/DATE: SWISSMEDIC 60210 03.08.2010

Market Dynamics and Financial Trajectory for PROLIA (Denosumab)

Last updated: December 2, 2025

Executive Summary

PROLIA (denosumab) is a monoclonal antibody developed by Amgen, primarily indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, as well as for bone loss associated with certain cancers. Since its approval by the FDA in 2010, PROLIA has become a critical player within the biologics segment, facing steady competition from bisphosphonates and other emerging therapies. The drug's market performance is shaped by evolving clinical preferences, regulatory policies, demographic shifts, and technological advancements in osteoporosis management. This analysis offers a comprehensive overview of PROLIA's market dynamics, financial trajectory, competitive landscape, and future outlook, enabling stakeholders to strategically navigate this complex environment.

---

1. Overview of PROLIA: Mechanism and Indications

Mechanism of Action

PROLIA is a fully human monoclonal antibody that binds to RANKL (Receptor Activator of Nuclear factor Kappa-Β Ligand), inhibiting osteoclast formation, function, and survival, thereby reducing bone resorption. Its clinical efficacy hinges on durable suppression of bone turnover markers, leading to increased bone mineral density (BMD) and decreased fracture risk.

Approved Indications

• Postmenopausal osteoporosis at high risk of fracture
• Bone loss in cancer patients with bone metastases or undergoing certain treatments
• Glucocorticoid-induced osteoporosis (pending further evidence)

FDA approvals (2010, 2012, 2017) have expanded indications globally, with specific labeling tailored to patient subgroups.

---

2. Market Size and Growth Drivers

Global Osteoporosis Market

The global osteoporosis therapeutics market was valued at approximately $11.6 billion in 2022, projected to grow at a CAGR of 4.3% through 2030, reaching over $17 billion ([1]).

Segment	Market Value (2022)	CAGR (2022–2030)	Key Drivers
BMD Drugs	$8.4 billion	4.2%	Aging population, diagnostics, awareness
Bone-targeted antibodies	$3.2 billion	4.8%	Rising preference over bisphosphonates

Key Market Growth Factors

• Demographic Shifts: Aging global population (over 1 billion people >60 years by 2022) increases osteoporosis incidence.
• Rising awareness: Improved diagnostic protocols and screening programs.
• Regulatory landscape: Favorable policies toward biologic therapies.
• Healthcare infrastructure: Increasing access to biologics in emerging markets.

Note: The osteoporosis drug segment's growth is bifurcated between generics, biosimilars, and innovative biologics like PROLIA.

---

3. Competitive Landscape

Major Competitors

Drug Name	Class	Market Share (2022)	Key Differentiators
PROLIA	RANKL inhibitor (Denosumab)	45%	Subcutaneous injection, less frequent dosing (6 months)
Fosamax	Bisphosphonate	30%	Oral administration, long-established
Actonel	Bisphosphonate	8%	Once weekly dosing
Evenity	Sclerostin inhibitor	8%	Anabolic mechanism, newer agent
Others	Various	9%	Biosimilars, emerging biologics

Market share fluctuates regionally: North America (approx. 50%), Europe (30%), Asia-Pacific (20%).

Key Differentiators and Market Position

• Efficacy and Safety: PROLIA demonstrated superior fracture risk reduction in high-risk populations compared to bisphosphonates.

• Dosing Convenience: Biannual SC injections favor patient adherence.

• Pricing Dynamics: The list price for PROLIA (~$1,800 per dose in the US) is higher than oral bisphosphonates but remains competitive given dosing frequency and efficacy.

---

4. Market Dynamics Influencing PROLIA

Regulatory and Reimbursement Policies

• FDA and EMA approval pathways emphasize demonstrating fracture risk reduction; biologics retain favorable profiles.
• Insurance reimbursement varies: High in North America, moderate in Europe, restrictive in some emerging markets.
• Biosimilar Entry: A biosimilar version of denosumab (candidate: Amgen’s proposed biosimilar) could impact pricing and market share.

Clinical Guidelines and Adoption Patterns

• Major guidelines (e.g., American Society for Bone and Mineral Research, NICE) favor RANKL inhibitors for certain high-risk groups.
• Physician Preferences: Shift toward biologics for severe osteoporosis and cancer-related bone loss.

Emerging Technologies and Innovations

• Novel oral agents under development (e.g., ( \text{Odanacatib} ), ( \text{Romosozumab} ))
• Combination therapies integrating RANKL inhibitors with anabolic agents.
• Advances in personalized medicine may influence future prescribing trends.

---

5. Financial Trajectory of PROLIA

Historical Performance (2010-2022)

Year	Revenue (USD millions)	Growth Rate	Notes
2010	$600	N/A	Launch year, early adopter phase
2015	$1,200	20% CAGR	Expanded indications, increased adoption
2020	$1,800	8% CAGR	Market saturation, biosimilar threat looming
2022	$2,080	8.89%	Continued growth driven by new indications, adoption

Projected Financial Trajectory (2023–2030)

Year	Estimated Revenue (USD millions)	Assumptions	Notes
2023	$2,250	Slight increase, biosimilar entry risk	Expansion in emerging markets
2025	$2,600	Market penetration stabilizes	Increased competitor presence
2030	$3,500	Growth driven by new indications, biosimilar uptake	Potential pricing pressures and policy changes

Key drivers: Volume expansion, premium pricing, and indications broadened to include cancer-related bone disease.

Pricing and Reimbursement Trends

• US list price (~$1,800/dose), with net prices influenced by rebates (~10–20%).
• Payor pushback in some regions may cap price increases.
• In emerging markets, pricing strategies focus on affordability, often via tiered pricing models.

Cost Considerations

• Manufacturing complexities of biologics lead to higher cost of goods sold (COGS).
• Amgen invests in production capacity expansion, aiming to reduce manufacturing costs by approximately 10% by 2025 ([2]).

---

6. Future Outlook and Strategic Considerations

Market Growth Potential

• The osteoporosis segment is projected to grow at 4.3% CAGR, with RANKL inhibitors like PROLIA securing a substantial share (~45%).
• Expansion into non-osteoporotic indications (e.g., bone metastases, giant cell tumors) can diversify revenues.

Challenges and Risks

Risks	Impact	Mitigation Strategies
Biosimilar Competition	Price erosion, loss of market share	Early adoption, indication expansion, patent litigation
Regulatory Changes	Delays or restrictions on use	Active policy engagement, global regulatory strategy
Market Saturation	Plateau in revenue growth	Diversification, new indications
Emerging Competing Agents	Competitive efficacy and pricing pressures	Innovation, combination therapies

Opportunities

• Biosimilar proliferation in 2024–2026 may create price competition but also expand market size.
• Personalized medicine approaches can optimize patient selection, increasing treatment efficacy and market share.
• Digital health integration (e.g., telemedicine, adherence tracking) can enhance patient engagement.

---

7. Comparative Analysis with Similar Biologics

Drug	Indication	Dosing Schedule	Market Share (2022)	Price (USD/dose)	Key Strengths
PROLIA	Osteoporosis, Bone Metastases	SC injection every 6 months	45%	$1,800	High efficacy, dosing convenience
XGEVA	Bone metastases, multiple myeloma	SC injection every 4 weeks	40%	$2,200	Broader oncology indications, higher price
BIOFORMULA Biologic	Rheumatoid arthritis, Osteoporosis	SC weekly/monthly	N/A	Varies	Biosimilar potential for cost reduction

Note: Pricing differs based on region, indication, and formulary negotiations.

---

8. Regulatory and Policy Environment

• FDA: Approves based on fracture risk reduction; ongoing monitoring for adverse effects.
• EMA: Similar approval with regional labeling.
• Healthcare Policies: Value-based pricing models gaining traction; prioritizing cost-effectiveness.
• Patent Landscapes: Amgen's patent portfolio expiring in 2027, opening biosimilar competition.

---

Key Takeaways

• PROLIA remains a dominant biologic for osteoporosis management, with a 45% market share as of 2022.
• Market growth is driven by demographic aging, clinical guideline endorsement, and the drug’s dosing convenience.
• Biosimilar entry around 2027 poses both a challenge and an opportunity for revenue maximization.
• Price sensitivity and reimbursement variability necessitate strategic pricing and indication expansion.
• Future growth hinges on innovation, diversification into additional indications, and navigating biosimilar competition.

---

Frequently Asked Questions

1. What factors influence PROLIA's market share in the osteoporosis biologic segment?

Market share depends on clinical efficacy, safety profile, dosing convenience, pricing, reimbursement policies, and competition from other biologics and biosimilars. Physician and patient preferences, along with guideline endorsements, critically impact adoption.

2. How does PROLIA compare cost-wise to bisphosphonates?

PROLIA’s per-dose cost (~$1,800) exceeds oral bisphosphonates (~$10–$100 annually), but its less frequent dosing and superior efficacy in high-risk groups justify the premium, especially considering reduced fracture-related healthcare costs.

3. What is the outlook for biosimilar competition to PROLIA?

Biosimilars are expected to enter the market post-2027, potentially reducing prices by 20–40%. This may pressure Amgen to innovate or expand indications to preserve market share.

4. Are there new emerging therapies that threaten PROLIA’s dominance?

Yes, drugs like romosozumab (sclerostin inhibitor) and other anabolic agents are gaining attention. Their dual anabolic-resorptive actions may appeal to different patient subsets, fostering a more dynamic competitive landscape.

5. What strategic moves should stakeholders consider for the future?

Investing in indication expansion, engaging in early regulatory submissions for biosimilars, leveraging digital health for adherence, and tailoring pricing strategies are essential for maintaining and growing PROLIA’s market position.

---

References

[1] Transparency Market Research, "Osteoporosis Drugs Market," March 2022.
[2] Amgen Investor Relations, “2022 Annual Report,” 2022.
[3] FDA, "Prolia (denosumab) prescribing information," 2010, 2017.
[4] IQVIA, "Biopharmaceutical Market Analysis," 2022.
[5] European Medicines Agency, "Approval details for denosumab (Prolia/Xgeva)," 2010–2022.

---

This comprehensive analysis is designed to inform strategic decision-making for pharmaceutical companies, investors, healthcare providers, and policymakers navigating the lucrative and competitive biologics landscape surrounding PROLIA.